AU2007253212B2 - Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof - Google Patents

Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof Download PDF

Info

Publication number
AU2007253212B2
AU2007253212B2 AU2007253212A AU2007253212A AU2007253212B2 AU 2007253212 B2 AU2007253212 B2 AU 2007253212B2 AU 2007253212 A AU2007253212 A AU 2007253212A AU 2007253212 A AU2007253212 A AU 2007253212A AU 2007253212 B2 AU2007253212 B2 AU 2007253212B2
Authority
AU
Australia
Prior art keywords
proinsulin
nucleotide sequence
sequence
human
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007253212A
Other languages
English (en)
Other versions
AU2007253212A1 (en
Inventor
Rima Barhoum Tannous
Fatima Bosch Tubert
Patricia Boya Tremoleda
Silvia Corrochano Sanchez
Enrique J. De La Rosa Cano
Pedro De La Villa Polo
Maria Flora De Pablo Davila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universitat Autonoma de Barcelona UAB, Universidad de Alcala de Henares UAH filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of AU2007253212A1 publication Critical patent/AU2007253212A1/en
Assigned to UNIVERSIDAD DE ALCALA DE HENARES, UNIVERSITAT AUTONOMA DE BARCELONA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS reassignment UNIVERSIDAD DE ALCALA DE HENARES Alteration of Name(s) of Applicant(s) under S113 Assignors: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, UNIVERSIDAD AUTONOMA DE BARCELONA, UNIVERSIDAD DE ALCALA DE HENARES
Application granted granted Critical
Publication of AU2007253212B2 publication Critical patent/AU2007253212B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2007253212A 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof Ceased AU2007253212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200601314 2006-05-22
ES200601314A ES2331342B1 (es) 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
PCT/ES2007/070097 WO2007135220A1 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones

Publications (2)

Publication Number Publication Date
AU2007253212A1 AU2007253212A1 (en) 2007-11-29
AU2007253212B2 true AU2007253212B2 (en) 2012-09-27

Family

ID=38722988

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007253212A Ceased AU2007253212B2 (en) 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof

Country Status (7)

Country Link
US (1) US20100330042A1 (https=)
EP (1) EP2042189B1 (https=)
JP (1) JP4727748B2 (https=)
AU (1) AU2007253212B2 (https=)
CA (1) CA2652983C (https=)
ES (2) ES2331342B1 (https=)
WO (1) WO2007135220A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2104380A (en) * 1981-08-27 1983-03-09 Lilly Co Eli Human proinsulin pharmaceutical formulations
WO2000004171A1 (en) * 1998-07-15 2000-01-27 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
US20030220229A1 (en) * 1994-07-08 2003-11-27 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type I diabetes
US20040053817A1 (en) * 2000-11-08 2004-03-18 Detlef Mohr Delayed-release pharmaceutical formulations
WO2004083234A2 (en) * 2003-03-14 2004-09-30 Nobex Corporation Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2104380A (en) * 1981-08-27 1983-03-09 Lilly Co Eli Human proinsulin pharmaceutical formulations
US20030220229A1 (en) * 1994-07-08 2003-11-27 Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type I diabetes
WO2000004171A1 (en) * 1998-07-15 2000-01-27 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
US20040053817A1 (en) * 2000-11-08 2004-03-18 Detlef Mohr Delayed-release pharmaceutical formulations
WO2004083234A2 (en) * 2003-03-14 2004-09-30 Nobex Corporation Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diaz, B. et al. 1999 Euro. J. Neurosci. vol. 11, pp. 1624-1632 *
Diaz, B. et al. 2000 Develop. vol. 127, pp. 1641-1649 *

Also Published As

Publication number Publication date
CA2652983C (en) 2016-07-19
EP2042189A1 (en) 2009-04-01
ES2331342B1 (es) 2010-10-13
ES2433389T3 (es) 2013-12-10
ES2331342A1 (es) 2009-12-29
WO2007135220A1 (es) 2007-11-29
CA2652983A1 (en) 2007-11-29
AU2007253212A1 (en) 2007-11-29
EP2042189A4 (en) 2010-02-17
JP2009537612A (ja) 2009-10-29
EP2042189B1 (en) 2013-06-26
US20100330042A1 (en) 2010-12-30
JP4727748B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
Kobayashi et al. HRG4 (UNC119) mutation found in cone–rod dystrophy causes retinal degeneration in a transgenic model
Petters et al. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa
Pang et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEβ mutation
Matsuo et al. Mouse Otx2 functions in the formation and patterning of rostral head.
US6204251B1 (en) Ocular gene therapy
JP6827320B2 (ja) ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法
Hu et al. In vivo CRISPR/Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa
Shiels TRPM3_miR-204: a complex locus for eye development and disease
US20070264244A1 (en) Pigment epithelial cell of the eye, its production and use in therapy of an eye or CNS disease
WO1996013276A9 (en) Ocular gene therapy
RU2251838C2 (ru) Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование
Jones et al. Retinal expression of γ-crystallins in the mouse
Palmer et al. Expression of Gtf2ird1, the Williams syndrome-associated gene, during mouse development
US11351225B2 (en) Methods for modulating development and function of photoreceptor cells
Stieger et al. Adeno-associated virus mediated gene therapy for retinal degenerative diseases
AU2007253212B2 (en) Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
EP1360898A1 (en) Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
JP2002087983A (ja) 筋萎縮性側索硬化症治療剤
Yokoyama et al. Genomic structure and functional characterization of NBPhox (PMX2B), a homeodomain protein specific to catecholaminergic cells that is involved in second messenger-mediated transcriptional activation
JP2023038873A (ja) 遺伝子改変型ゼブラフィッシュ
CN113956345B (zh) Angpt4蛋白及其编码基因在调控心脏损伤后的修复与再生能力中的应用
WO1998015628A1 (fr) Nouveau gene de semaphorine: la semaphorine w
WO2005023311A2 (en) Novel targets for the treatment of retina diseases
CN121674478A (zh) 一种用于prpf31基因治疗药效及安全性评价的小鼠模型
Ramon et al. Molecular biology of retinitis pigmentosa: therapeutic implications

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired